Duality Biotherapeutics Announces Share Repurchase Plan and Chairman’s Proposed Shareholding Increase
Key Points for Investors
- Share Repurchase Plan: Duality Biotherapeutics, Inc. (“Duality” or “the Company”) has announced its intention to repurchase shares in the open market under a general mandate approved by shareholders at the upcoming annual general meeting on June 20, 2025. The repurchase plan allows for up to US\$40 million to be used for buying back shares, with the repurchased shares to be held as treasury shares.
- Board’s Confidence in Company Value: The Board believes that the current trading price of Duality’s shares does not reflect their intrinsic value and underlying business prospects. The repurchase plan is positioned as a demonstration of the Board and management’s confidence in the long-term strategy and growth potential of the Company.
- Regulatory Compliance: The share repurchase will be conducted in accordance with the Company’s articles, the Hong Kong Stock Exchange Listing Rules, and all relevant legal requirements.
- Chairman’s Proposed Shareholding Increase: Dr. Zhu Zhongyuan, the founder, chairman, executive director, and CEO, has notified the Board of his intention to increase his personal stake in Duality by purchasing up to US\$5 million worth of shares on the open market using his own funds.
- Potential Price Sensitivity: Both the share repurchase plan and the chairman’s proposed acquisition of shares are highly price-sensitive events. These moves may signal to the market a belief in undervaluation and could potentially lead to positive movement in the share price, as they reflect direct insider confidence in the business and its prospects.
- Investor Advisory: Shareholders and potential investors are advised to exercise caution when trading Duality’s securities due to the possible implications of these developments.
Detailed Article
Duality Biotherapeutics, Inc., a Cayman Islands-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange (Stock Code: 9606), has made a significant voluntary announcement regarding its capital management strategy and the confidence of its leadership team in the Company’s future.
The Company’s Board of Directors intends to utilize a general mandate, which will be granted at the annual general meeting scheduled for June 20, 2025, to initiate a substantial share repurchase program. A total of up to US\$40 million from internal funds will be allocated for repurchasing shares in the open market. These repurchased shares will be held as treasury shares, potentially reducing the supply of shares available in the market and enhancing shareholder value over the long term.
This strategic move comes as the Board assesses the Company’s current share price as being below its intrinsic value and not reflective of its robust business prospects. The repurchase plan is therefore a strong indicator of the Board and management’s confidence in the long-term strategy and growth trajectory of Duality Biotherapeutics.
In a separate but related development, Dr. Zhu Zhongyuan, the founder, chairman, executive director, and CEO, has formally declared his intention to increase his personal shareholding in Duality. Dr. Zhu plans to acquire up to US\$5 million worth of shares in the open market, using his own funds. This action is subject to compliance with the Hong Kong Listing Rules and relevant laws and regulations.
The combination of a major share repurchase and insider buying by the Company’s top executive is a compelling signal for investors. Such actions often indicate belief in undervaluation, and can be interpreted as a measure to support the share price, increase shareholder value, and demonstrate management’s alignment with investor interests.
Investors should note that these developments are highly price-sensitive and may lead to increased volatility or upward movement in Duality’s share price. The Company has advised all shareholders and potential investors to exercise caution when dealing in its securities.
As of the announcement date, the Company’s Board comprises Dr. Zhu Zhongyuan, Mr. Zhang Shaoren, Dr. Hua Haiqing (executive directors), Mr. Cai Zhiyang and Dr. Yu Tao (non-executive directors), and Mr. Xie Dong, Mr. Gao Fengyong, and Ms. Chuai Shuyin (independent non-executive directors).
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors are advised to consult with their financial advisers and exercise caution in trading Duality Biotherapeutics, Inc. securities. The Company’s announcements and regulatory filings should be reviewed for further detail.
雙合生物宣布股份回購計劃及董事長擬增持股份
投資者重點
- 股份回購計劃：雙合生物（Duality Biotherapeutics, Inc.）公佈將根據股東於2025年6月20日即將舉行的股東大會授出的普通授權，在公開市場回購股份。回購計劃最高動用資金達4,000萬美元，回購股份會作為庫藏股份持有。
- 董事會對公司價值的信心：董事會認為現時股份交易價格未能反映公司的真正價值及業務前景，是回購股份的良好時機。回購計劃亦反映董事會及管理層對公司長遠發展的信心。
- 合規事項：股份回購將根據公司章程、香港聯交所上市規則及其他相關法規進行。
- 董事長擬增持股份：公司創辦人、董事長、執行董事及行政總裁朱中元博士通知董事會，基於對集團前景及長期投資價值的信心，計劃以自有資金於公開市場增持股份，總額最高達500萬美元，該行動需遵守上市規則及相關法例。
- 潛在價格敏感：股份回購及董事長增持均屬極具價格敏感的消息，或反映公司被低估，管理層信心強，可能帶動股價正面走勢。
- 投資者需注意：公司建議股東及潛在投資者在買賣公司證券時保持謹慎。
詳細報導
雙合生物（Duality Biotherapeutics, Inc.），於開曼群島註冊並於香港聯交所上市（股份代號：9606），剛作出重要自願公佈，展示其資本管理策略及管理層對公司未來的信心。
公司董事會計劃利用即將於2025年6月20日股東大會授出的普通授權，啟動大規模股份回購計劃，最高動用公司內部資金4,000萬美元於公開市場回購股份，回購股份將作庫藏股份持有，或減少市場流通量，提升股東長遠價值。
董事會認為現時公司股價低於其內在價值，未能反映公司強勁業務前景，回購計劃是董事會及管理層對公司長遠策略及增長的信心表現。
另外，創辦人、董事長、執行董事及行政總裁朱中元博士正式通知董事會，計劃以自有資金於公開市場增持公司股份，總額最高達500萬美元，並需遵守上市規則及相關法規。
大規模股份回購及公司高層增持，均屬重大信號，反映公司被低估及管理層信心，可能帶動股價上升，增加股東價值，展現管理層與投資者利益一致。
投資者須注意，此舉動屬價格敏感，有機會令雙合生物股價波動或向上，公司建議各股東及投資者謹慎買賣公司證券。
截至公告日，公司董事會成員包括朱中元博士、張少仁先生、華海清博士（執行董事）、蔡志陽先生及余濤博士（非執行董事）、謝東先生、高豐勇先生及楚愛淑銀女士（獨立非執行董事）。
免責聲明
本文僅供參考，並不構成投資建議。投資者應咨詢財務顧問，謹慎交易雙合生物證券，並查閱公司公告及監管文件以了解詳情。
